Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves' orbitopathy: A five-year follow-up study

Autoimmunity

Volumn 47, Issue 8, 2014, Pages 548-555

  Erdei, Annamaria ^a   Paragh, Gyorgy ^a   Kovacs, Peter ^a   Karanyi, Zsolt ^a   Berenyi, Ervin ^a   Galuska, Laszlo ^a   Lenkey, Agota ^b   Szabados, Lajos ^a   Gyory, Ferenc ^b   Ujhelyi, Bernadett ^a   Berta, Andras ^a   Boda, Judit ^a   Berta, Eszter ^a   Bodor, Miklos ^a   Gazdag, Annamaria ^a   Nagy, Endre V ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Biological treatment; Endocrine orbitopathy; Graves'disease; Hyperthyroidism; Thyroid

Indexed keywords

DIPYRONE; GLUCONATE CALCIUM; LEVOTHYROXINE; METHYLPREDNISOLONE; PARACETAMOL; PENTETATE TECHNETIUM TC 99M; RITUXIMAB; THIAMAZOLE; THYROID ANTIBODY; THYROTROPIN RECEPTOR ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LIOTHYRONINE; MONOCLONAL ANTIBODY; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN; THYROTROPIN-BINDING INHIBITORY IMMUNOGLOBULIN; THYROXINE;

ADULT; ALLERGIC REACTION; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ACTIVITY SCORE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG TREATMENT FAILURE; ENDOCRINE OPHTHALMOPATHY; FEMALE; FOLLOW UP; HUMAN; IRRADIATION; LONG TERM CARE; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT HISTORY OF THYROIDECTOMY; RADIATION DOSE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERAPY EFFECT; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; BLOOD; GRAVES OPHTHALMOPATHY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; FOLLOW-UP STUDIES; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; THYROTROPIN; THYROXINE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRIIODOTHYRONINE;

EID: 84912093949     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2014.939266     Document Type: Article

References (35)

1. Weetman, A. P. 2000. Graves disease. New. Eng. J. Med. 343: 1236-1248
2. Menconi, F., C. Marcocci, and M. Marino. 2014. Diagnosis and classification of Graves disease. Autoimmune Rev. 13: 398-402
3. Burch, H. B., and L. Wartofsky. 1993. Graves ophthalmopathy: current concepts regarding pathogenesis and treatment. Endocr. Rev. 14: 747-793
4. Bahn, R. S. 2003. Pathophysiology of Graves ophthalmopathy: the cycle of disease. J. Clin. Endocrinol. Metab. 88: 1939-1946
5. Drexhage, H A. 2006. Are there more than antibodies to the thyroid-stimulating hormone receptor that meet the eye in Graves disease? Endocrinology. 147: 9-12
6. Mengistu, M., Y. G. Lukes, E. V. Nagy, et al. 1994. TSH receptor gene expression in retroocular fibroblasts. J. Endocrinol. Invest. 17: 437-441
7. Weightman, D. R., P. Perros, I. H. Sherif, and P. Kendall-Taylor. 1993. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity. 16: 251-257
8. Bartalena, L., and M. L. Tanda. 2009. Clinical practice. Graves ophthalmopathy. New Engl. J. Med. 360: 994-1001
9. Pescivitz, M. D. 2006. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am. J. Transpl. 6: 859-866
10. Nadler, L. M., J. Ritz, R. Hardy, et al. 1981. An unique cell surface antigen identifying lymphoid malignancies of B cell origin. J. Clin. Invest. 67: 134-140
11. Reff, M. E., K. Carner, K. S. Chambers. 1994. Depletion of B cells in vivo by a chimerec mouse human monoclonal antibody to CD20. Blood. 83: 435-445
12. Maloney, D. G., B. Smith, and F. R. Apelbaum. 1996. The antitumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkins lymphoma (NHL) cell lines. Blood. 88: 637a
13. El Fassi, D., C. H. Nielsen, H. C. Hasselbalch, and L. Hegedüs. 2006. The rationale for B lymphocyte depletion in Graves disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur. J. Endocrinol. 154: 623-632
14. El Fassi, D., O. Clemmensen, C. H. Nielsen, et al. 2007. Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Grave disease. J. Clin. Endocrinol. Metab. 92: 3762-3763
15. Salvi, M., G. Vannucchi, I. Campi, et al. 2006. Efficacy of rituximab treatment for thyroid-Associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur. J. Endocrinol. 154: 511-517
16. Salvi, M., G. Vannucchi, I. Campi, et al. 2007. Treatment of Graves disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open tudy. Eur. J. Endocrinol. 156: 33-40
17. El Fassi, D., C. H. Nielsen, H. C. Hasselbalch, and L. Hegedüs. 2006. Treatment-resistant severe, active Graves ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid. 16: 709-710
18. Bonara, P., G. Vannucchi, I. Campi, et al. 2008. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for grave ophthalmopathy. Clin. Rev. Allergy Immunol. 34: 118-123
19. Salvi, M., G. Vannucchi, I. Campi, et al. 2009. Rituximab treatment in a patient with severe thyroid-Associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin. Immunol. 131: 360-365
20. Salvi, M., G. Vannucchi, I. Campi, et al. 2008. New immunomodulators in the treatment of Graves ophthalmopathy. Ann. Endocrinol. (Paris). 69: 153-156
21. Datta, S. K. 2009. Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells. Nat. Clin. Pract. Rheumatol. 5: 80-82
22. Nielsen, J. F., D. El Fassi, and C. H. Nielsen, et al. 2009. Evidence of orbital B and T cell depletion after rituximab therapy in Grave ophthalmopathy. Acta Ophthalmol. 87: 927-929
23. Mourits, M. P., M. F. Prummel, W. M. Wiersinga, and L. Koorneef. 1997. Clinical activity score as a guide in the management of patients with Graves ophthalmopathy. Clin. Endocrinol. 47: 9-14
24. Galuska, L., A. Leovey, Z. Szucs-Farkas, et al. 2005. Imaging of disease activity in Graves orbitopathy with different methods: comparison of (99m)Tc-DTPA and (99m)Tc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores. Nucl. Med. Commun. 26: 407-414
25. Ujhelyi, B., A. Erdei, L. Galuska, et al. 2009. Retrobulbar 99mTc-diethylentriamine-pentaacetic-Acid uptake may predict the effectiveness of immunosippressive therapy in Graves ophtalmopathy. Thyroid. 19: 375-380
26. El Fassi, D., C. H. Nielsen, S. J. Bonnema, et al. 2007. B lymphocyte depletion with the monoclonal antibody rituximab in Graves disease: a controlled pilot study. J. Clin. Endocrinol. Metab. 92: 1769-1772
27. Heemstra, K., R. Toes, J. Sepers, et al. 2008. Rituximab in relapsing Graves disease, a phase II study. Eur. J. Endocrinol. 159: 609-615
28. Chong, K. K., D. Khanna, N. F. Afifiyan, et al. 2010. Rituximab treatment of patients with severe, corticosteroid-resistant thyroidassociated ophthalmopathy. Ophtalmology. 117: 133-139
29. Vannucchi, G., I. Campi, M. Bonomi, et al. 2010. Rituximab treatment in patients with active Graves orbitopathy: effects on proinflammatory and humoral immune reactions. Clin. Exp. Immunol. 161: 436-443
30. Mitchell, A. L., E. H. Gan, M. Morris, et al. 2013. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves orbitopathy. Clin. Endocrinol. 79: 437-442
31. Salvi, M., G. Vannucchi, N. Currò, et al. 2012. Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action Arc. Ophthalmol. 130: 122-124
32. Savino, G., L. Balia, D. Colucci, et al. 2013. Intraorbital injection of rituximab: a new approach for active thyroid-Associated orbitopathy, a prospective case series. Minerva. Endocrinol. 38: 173-179
33. El Fassi, D., C. H. Nielsen, P. Junker, et al. 2011. Systemic adverse events following rituximab therapy in patients with Graves disease. J. Endocrinol. Invest. 34: 163-167
34. Shawn, S., and A. R. Ahmed. 2013. Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Autoimmunity. 46: 487-496
35. Kahaly, G., S. Plitz, W. Müller-Forell, and G. Hommel. 1996. Randomized trial of intravenous immunoglobulins versus prednisolon in Graves ophtalmopathy. Clin. Exp. Immunol. 106: 197-202